News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
336,484 Results
Type
Article (20250)
Company Profile (129)
Press Release (316104)
Multimedia
Podcasts (79)
Webinars (13)
Section
Business (105511)
Career Advice (882)
Deals (18556)
Drug Delivery (97)
Drug Development (50847)
Employer Resources (79)
FDA (7729)
Job Trends (7767)
News (186142)
Policy (17383)
Tag
Academia (737)
Accelerated approval (4)
Adcomms (20)
Allergies (48)
Alliances (27933)
ALS (61)
Alzheimer's disease (657)
Antibody-drug conjugate (ADC) (114)
Approvals (7744)
Artificial intelligence (168)
Autoimmune disease (20)
Automation (7)
Bankruptcy (177)
Best Places to Work (5553)
BIOSECURE Act (13)
Biosimilars (101)
Biotechnology (57)
Bladder cancer (46)
Brain cancer (21)
Breast cancer (143)
Cancer (1322)
Cardiovascular disease (128)
Career advice (716)
Career pathing (21)
CAR-T (63)
CDC (6)
Cell therapy (168)
Cervical cancer (6)
Clinical research (43094)
Collaboration (556)
Compensation (208)
Complete response letters (23)
COVID-19 (1111)
CRISPR (32)
C-suite (195)
Cystic fibrosis (64)
Data (1502)
Decentralized trials (2)
Denatured (19)
Depression (32)
Diabetes (159)
Diagnostics (1826)
Digital health (6)
Diversity (7)
Diversity, equity & inclusion (22)
Drug discovery (88)
Drug pricing (131)
Drug shortages (32)
Duchenne muscular dystrophy (72)
Earnings (39575)
Editorial (35)
Employer branding (10)
Employer resources (74)
Events (49286)
Executive appointments (527)
FDA (8494)
Friedreich's ataxia (3)
Frontotemporal dementia (2)
Funding (381)
Gene editing (60)
Generative AI (18)
Gene therapy (171)
GLP-1 (634)
Government (1889)
Grass and pollen (3)
Guidances (92)
Healthcare (5910)
Huntington's disease (15)
IgA nephropathy (27)
Immunology and inflammation (100)
Immuno-oncology (5)
Indications (24)
Infectious disease (1194)
Inflammatory bowel disease (93)
Inflation Reduction Act (9)
Influenza (25)
Intellectual property (69)
Interviews (116)
IPO (7397)
IRA (47)
Job creations (2437)
Job search strategy (648)
Kidney cancer (8)
Labor market (34)
Layoffs (295)
Leadership (16)
Legal (4131)
Liver cancer (32)
Lung cancer (197)
Lymphoma (115)
Machine learning (5)
Management (30)
Manufacturing (260)
MASH (60)
Medical device (1971)
Medtech (1974)
Mergers & acquisitions (11468)
Metabolic disorders (567)
Multiple sclerosis (58)
NASH (20)
Neurodegenerative disease (64)
Neuropsychiatric disorders (25)
Neuroscience (1036)
NextGen: Class of 2025 (2360)
Non-profit (910)
Now hiring (27)
Obesity (353)
Opinion (197)
Ovarian cancer (40)
Pain (84)
Pancreatic cancer (51)
Parkinson's disease (92)
Partnered (11)
Patents (172)
Patient recruitment (63)
Peanut (17)
People (33705)
Pharmaceutical (74)
Pharmacy benefit managers (24)
Phase I (13516)
Phase II (18222)
Phase III (14634)
Pipeline (964)
Policy (152)
Postmarket research (1619)
Preclinical (4743)
Press Release (29)
Prostate cancer (78)
Psychedelics (16)
Radiopharmaceuticals (166)
Rare diseases (276)
Real estate (3178)
Recruiting (29)
Regulatory (12704)
Reports (24)
Research institute (822)
Resumes & cover letters (139)
Rett syndrome (1)
RNA editing (5)
RSV (26)
Schizophrenia (69)
Series A (71)
Series B (40)
Service/supplier (7)
Sickle cell disease (38)
Special edition (17)
Spinal muscular atrophy (113)
Sponsored (12)
Startups (2016)
State (2)
Stomach cancer (9)
Supply chain (56)
Tariffs (59)
The Weekly (58)
Vaccines (302)
Venture capitalists (34)
Weight loss (254)
Women's health (14)
Worklife (8)
Date
Last 7 days (263)
Last 30 days (1236)
Last 365 days (16197)
2025 (7715)
2024 (17679)
2023 (19648)
2022 (25867)
2021 (26639)
2020 (24871)
2019 (20058)
2018 (15588)
2017 (17254)
2016 (16202)
2015 (18801)
2014 (14787)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12738)
Location
Africa (410)
Alabama (27)
Alaska (1)
Arizona (70)
Arkansas (8)
Asia (25128)
Australia (3243)
California (3064)
Canada (1270)
China (420)
Colorado (118)
Connecticut (120)
Delaware (94)
Europe (51925)
Florida (550)
Georgia (68)
Idaho (17)
Illinois (296)
India (21)
Indiana (194)
Iowa (3)
Japan (160)
Kansas (67)
Kentucky (20)
Louisiana (3)
Maine (4)
Maryland (422)
Massachusetts (2555)
Michigan (53)
Minnesota (154)
Mississippi (2)
Missouri (29)
Montana (10)
Nebraska (11)
Nevada (23)
New Hampshire (8)
New Jersey (1217)
New Mexico (21)
New York (901)
North Carolina (560)
North Dakota (2)
Northern California (1308)
Ohio (91)
Oklahoma (5)
Oregon (21)
Pennsylvania (704)
Puerto Rico (14)
Rhode Island (18)
South America (609)
South Carolina (5)
Southern California (1253)
Tennessee (44)
Texas (402)
United States (12056)
Utah (66)
Virginia (105)
Washington D.C. (53)
Washington State (248)
West Virginia (1)
Wisconsin (29)
336,484 Results for "biohaven pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Neurodegenerative disease
FDA Delays Decision Date on Biohaven’s Spinocerebellar Ataxia Application
The FDA also changed its tune and is now planning to convene an advisory committee to discuss Biohaven’s application.
May 15, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Biohaven Grabs a Foothold With $600M Windfall From Oberland Capital
Biohaven will use the money to bankroll commercial preparations for the spinocerebellar ataxia drug candidate troriluzole, which is currently under FDA review with a decision expected in the third quarter.
April 29, 2025
·
2 min read
·
Tristan Manalac
Neuropsychiatric disorders
Biohaven Disappoints Again, This Time in Phase II/III Bipolar Mania Trial
Biohaven in recent months has reported a clinical stumble in spinal muscular atrophy, alongside a Phase I readout for its protein degrader candidate that investors found underwhelming.
March 4, 2025
·
2 min read
·
Tristan Manalac
Legal
Pfizer Settles Biohaven Kickback Suit for Nearly $60M
From March 2020 through September 2022, Biohaven wielded meals at high-end restaurants and paid speaking opportunities to induce healthcare providers to prescribe its migraine therapy Nurtec ODT, according to the Department of Justice.
January 27, 2025
·
2 min read
·
Tristan Manalac
Antibody-drug conjugates
Merus and Biohaven Strike New ADC Collaboration
On the heels of an FDA approval for its monoclonal antibody Bizengri, Merus will generate three novel cancer-targeting antibodies that it will pass over to Biohaven to link into antibody drug-conjugates.
January 13, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments
May 13, 2025
·
17 min read
Press Releases
Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development
June 11, 2025
·
6 min read
Neurodegenerative disease
Biohaven Drug Misses in Phase III for SMA, Will Be Tested in Obesity
While taldefgrobep alfa failed to show improved motor function in spinal muscular atrophy, treated patients saw a marked reduction in body fat. Biohaven plans to launch a Phase II trial in obesity by the end of the year.
November 25, 2024
·
2 min read
·
Tristan Manalac
Neurodegenerative disease
Biohaven Sets Stage for Comeback With Pivotal Study Results in Spinocerebellar Ataxia
The FDA previously refused to review Biohaven’s candidate in the indication due to a failed late-stage trial. However, the company is now planning to file an NDA in the fourth quarter of 2024.
September 24, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Biohaven’s Phase I Data for Lead Protein Degrader Disappoints Investors
Despite Biohaven’s bispecific protein degrader cutting autoantibody IgG levels by up to 37% in an early-stage study, investors saw it as “below the high bar” of 60%, according to William Blair analysts.
May 30, 2024
·
2 min read
·
Tristan Manalac
1 of 33,649
Next
